Abstract: BRAF V600E mutation, a missense mutation in exon 15 resulting in valine substitution for glutamate at position 600 within the kinase domain of BRAF oncogene, is found in a subset of lung adenocarcinoma (ADC). The usefulness of immunohistochemistry (IHC) as an alternative diagnostic tool has not been validated. Moreover, the clinical information of patients with BRAF V600E-mutated lung ADC is limited. We retrospectively identified 31 lung ADCs diagnosed with BRAF V600E mutation by standard molecular sequencing methods and reviewed their clinical characteristics and pathological features. An anti-BRAF V600E monoclonal VE1 antibody for IHC was used to confirm the expression patterns. The series was comprised of 99 cases, 29 with BRAF V600E mutation and 70 without BRAF V600E but with other types or undetected mutations. The majority of BRAF V600E-mutated biopsied tissues were poorly differentiated and micropapillary patterns. Application of the IHC VE1 assay was highly feasible in primary/metastatic sites or effusion blocks, yielding positive findings in 28 of 29 (96.6%) BRAF V600E-mutated tumors and negative results in 69 of 70 (98.6%) tumors harboring other types or undetected mutations. Patients who received pemetrexed/platinum-based rather than mutation-targeted chemotherapy as the first-line therapy for metastatic disease showed median overall survival of 15.5 months. Our findings indicated that VE1 antibody-based IHC analysis demonstrated high sensitivity and specificity to detect BRAF V600E-mutated lung ADCs in tissues from primary or metastatic sites.
Introduction
In the past decade, individualizing molecular targeted therapy based on specific driver oncogene aberrations has provided a powerful and favorable approach to the treatment of non-small cell lung cancer (NSCLC) [1] [2] [3] . One of the important driver gene mutations, which leads to signaling pathway dysregulation in lung cancer, occurs in v-raf murine sarcoma viral oncogenes homolog B1 (BRAF) [4] . BRAF protein, a member of the RAF (rapidly accelerated fibrosarcoma) family of serine/threonine protein kinases, functions to regulate the mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) pathway. Extracellular signaling activates RAS, a member of the superfamily of guanine nucleotide triphosphatases (GTPases), and subsequently phosphorylates downstream BRAF. Mutations in the BRAF kinase domain lead to increased BRAF kinase activity and can initiate tumorigenesis [5] . In particular, a thymine to adenine single-base change at position 1799 in exon 15 , which results in the V600E mutation, is observed in 1-2% of lung ADC [6] . This mutation has been shown to exhibit higher basal kinase activity than that of the wild-type protein [7] , and increase transforming capacity in NIH3T3 cells [8] . A lung cancer mouse model by inducible expression of BRAF V600E in the lung epithelial compartment led to development of lung adenocarcinoma in vivo. Deinduction of BRAF V600E decreased the level of constitutively activated MAPK pathway and led to lung tumor regression [9] . Recently, the U.S. Food and Drug Administration (FDA) approved the combination of dabrafenib and trametinib for the treatment of patients with BRAF V600E mutation-positive NSCLC [10] . Currently, the standard diagnostic method approved by the FDA is the next-generation sequencing oncology panel test (Oncomine™ Dx Target Test, Thermo Fisher Scientific Inc. USA), which has been shown to accurately and reliably detect patients with NSCLC carrying the BRAF V600E mutation [10] .
Nevertheless, the best treatment strategies may not always be feasible in real-world practice because of the increased expense of diagnostic tools and targeted medications. Alternative diagnostic approaches and other treatments of choice should also be considered. Recently, detection of the BRAF V600E mutation by immunohistochemistry (IHC) using the anti-BRAF V600E monoclonal VE1 antibody was found to be possible in melanoma, thyroid carcinoma, and colorectal cancer [11] [12] [13] [14] [15] . In NSCLC, only few previous studies that compared the sensitivity and specificity of clone VE1 in detecting BRAF V600E mutation with those of other molecular methodologies [16, 17] . Therefore, more studies need to be conducted to elucidate whether IHC with the VE1 antibody might be suitable as an alternative method to detect BRAF V600E mutation in patient with lung ADC. Moreover, the clinical characteristics of patients with lung cancer carrying BRAF V600E mutation are not consistent across different studies [18] [19] [20] . In addition, little is known regarding the real-world clinical outcomes of current treatments in patients not receiving BRAF-targeted therapies. Therefore, in this study we conducted a retrospective study of the demographic features of East Asian patients with lung ADC, validated the diagnostic value of IHC for the detection of the BRAF V600E mutation, and analyzed the clinical outcomes.
Results

Clinical and Pathological Characteristics of BRAF V600E Mutation-Positive Patients with Lung ADC
The clinical characteristics of 31 patients harboring primary BRAF V600E mutation and 700 patients with non-BRAF V600E mutations (without BRAF V600E but with other types or undetected mutations) in East Asian lung ADCs are listed in Table 1 . The non-BRAF V600E cases included 206 EGFR mutations, 56 ALK fusions, 26 KRAS mutations, 27 MET exon 14 deletion (MET ∆14 ) mutations, 16 HER2 mutations, 17 ROS1 fusions, 4 RET fusions, 8 BRAF non-V600E mutations, and 340 undetected mutations. For lung ADC patients with BRAF V600E, the median age was 67.0 (33 to 87) years; 52% (16 of 31) were men; 39% (12 of 31) were current/former smokers, averaging 40 ± 26 pack-years; and 77 % (24 of 31) had Stage IV NSCLC at initial diagnosis. None of the patients were identified as having concurrent BRAF V600E and EGFR, KRAS, ALK, HER2, MET ∆14 , ROS1, or RET gene alterations. Patients harboring BRAF V600E mutation tended to have poor Eastern Cooperative Oncology Group (ECOG) performance score (p = 0.024). There was no significant difference in age, gender, smoking status, stages at initial diagnosis, and numbers of metastatic sites between BRAF V600E mutated and non-mutated cases.
A total of 29 patients with lung ADC had available tumor samples to evaluate their pathological features. These tissues included surgically resected primary tumors (n = 7), bronchial or ultrasonography-guided biopsied primary tumors (n = 6), biopsies for metastatic sites (extrapulmonary lymph nodes, n = 5; bone metastasis, n = 1), and cell blocks created from malignant pleural effusion (n = 10). Among the 13 primary tumors diagnosed by surgically resected or biopsy specimens, micropapillary-predominant pattern was the most commonly observed morphologic type (9/13, 69%), followed by acinar-predominant (2/13), papillary-predominant (1/13), and solid-predominant pattern (1/13) ( Table 2) . For non-primary tumors with BRAF V600E mutation, the majority of the metastatic lymph nodes and all malignant pleural effusion blocks exhibited a micropapillary-predominant pattern. Table 1 . Clinical characteristics of patients with lung adenocarcinoma with BRAF V600E mutation (n = 31) or non-BRAF V600E mutations (n = 700). 
Clinical
Sensitivity of BRAF V600E (VE1) IHC: Results from 29 BRAF V600-Mutated Lung Cancers
Using criteria described in the materials and methods, 28 out of 29 lung ADCs (96.6%) with BRAF V600E mutation were positive for BRAF V600E (VE1) IHC (Table 3 ). The IHC staining intensity was weak in 9 cases (1+, 31%), moderate in 9 cases (2+, 31%), and strong in 11 cases (3+, 38%) ( Figure 1 ). The majority of samples exhibited positive cytoplasmic stain in > 80% of tumor cells (22/29, 76%), and 6 cases had positive stain in 60−75% of tumor cells (6/29, 21%). Only one case (case number 8, bronchial biopsy specimen in Table 2 ) showed weak cytoplasmic stain in only 10% of tumor cells and was considered as negative for the VE1 IHC test in this study (Figure 2a) . Overall, based on DNA/RNA sequencing data, our study demonstrated a sensitivity of 96.6% (28/29) for VE1 IHC to detect BRAF V600E mutation in lung ADCs. BRAF non-V600E (8) G469A (3) G469V (1) K483E (1) D594G (2) L597R (1) Sequencing 0 0
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Specificity of BRAF V600E (VE1) IHC: Results from 70 Lung Cancers without BRAF V600E Mutations
To determine the specificity of BRAF V600E (VE1) IHC, we randomly selected tumors diagnosed with BRAF non-V600E, EGFR, KRAS, HER2, MET ∆14 , ALK, ROS1, RET, or undetected mutations for this study (Table 2) . Among 70 cases, only one ALK-fusion-positive lung ADC exhibited both moderate nuclear and cytoplasmic positive staining in 80% of tumor cells (Figure 2b ), which was considered as a false positive case. In addition, a case with a ROS1 fusion detected by florescence in situ hybridization analysis showed weak positive cytoplasmic staining in 5% of tumor cells, which was considered as a negative result according to our criteria. Therefore, the specificity of VE1 IHC for tumors without BRAF V600E mutation in lung ADCs was 98.6% (69/70). 
To determine the specificity of BRAF V600E (VE1) IHC, we randomly selected tumors diagnosed with BRAF non-V600E, EGFR, KRAS, HER2, MET Δ14 , ALK, ROS1, RET, or undetected mutations for this study (Table 2) . Among 70 cases, only one ALK-fusion-positive lung ADC exhibited both moderate nuclear and cytoplasmic positive staining in 80% of tumor cells (Figure 2b ), which was considered as a false positive case. In addition, a case with a ROS1 fusion detected by florescence in situ hybridization analysis showed weak positive cytoplasmic staining in 5% of tumor cells, which was considered as a negative result according to our criteria. Therefore, the specificity of VE1 IHC for tumors without BRAF V600E mutation in lung ADCs was 98.6% (69/70). 
Clinical Outcomes of BRAF V600E-Mutated Lung ADCs without BRAF-Targeted Therapy
The detail duration of treatment regimens for patients with metastatic BRAF V600E-mutated lung cancers are shown in Figure 3a . Among 31 patients with lung ADC carrying BRAF V600E mutation, two patients (Case Numbers 2 and 7 in Table 2 ) did not relapse and were alive at final assessment. Another patient (Case Number 1 in Table 2 ) received surgery for a second primary lung cancer. At the data cut-off date, 28 patients had metastatic disease of which 23 received ≥1 line of systemic therapy for metastatic disease (Figure 3a) . For the first-line treatments, pemetrexed-platinum doublet chemotherapy was the most common regimen (13 patients, 57% of first-line recipients). Ten patients received other treatment regimens, including EGFR tyrosine kinase inhibitors (n = 6), gemcitabine/cisplatin chemotherapy (n = 1), navelbine/cisplatin regimen (n = 1); docetaxel/cisplatin regimen (n = 1), and immunotherapy (pembrolizumab, n = 1). Five patients received only best supportive care. and non-BRAF V600E with undetected mutation (n = 223). (c) Kaplan-Meier curves of overall survival in Stage IV BRAF V600E-mutated patients who received first-line therapy pemetrexed/platinum then maintenance pemetrexed (n = 13), other treatment regimens (n = 10), or best supportive care (n = 5). pvalues were calculated using a log-rank test. Symbols with "+" on the plot indicate censored patients.
Discussion
In the present study, we validated the clinical application of IHC using the VE1 antibody to detect BRAF V600E-mutated lung ADCs from primary lung cancer, metastatic tumors, or malignant pleural effusion cell blocks. We also observed that for patients who were unable to receive BRAFtargeted therapy because of financial issues, pemetrexed-containing regimens might be considered as an important treatment of choice for those with metastatic BRAF V600E-lung ADCs.
The VE1 mouse monoclonal antibody used in the present study constitutes an in vitro diagnostic IHC antibody produced against synthetic peptide sequence (GLATEKSRWSG) that represents the The duration of treatments with chemotherapy, targeted and non-targeted therapies, or immunotherapy for patients with metastatic BRAF V600E-mutant lung cancers. Symbol with "*" indicates no available tissue sample for BRAF VE1 immunohistochemistry analysis. (b) Kaplan-Meier curves of overall survival in patients with lung adenocarcinoma carrying BRAF V600E mutation (n = 24) and non-BRAF V600E with undetected mutation (n = 223). (c) Kaplan-Meier curves of overall survival in Stage IV BRAF V600E-mutated patients who received first-line therapy pemetrexed/platinum then maintenance pemetrexed (n = 13), other treatment regimens (n = 10), or best supportive care (n = 5). p-values were calculated using a log-rank test. Symbols with "+" on the plot indicate censored patients.
Overall survival (OS) for Stage IV lung ADC at initial diagnosis were analyzed in patients with BRAF V600E or with undetected mutation (no driver mutation/fusion detected in BRAF, EGFR, KRAS, ALK, ROS1, RET, HER2, or MET genes) (Figure 3b ). We observed that 24 patients with BRAF V600E mutation (median 10.8 months; 95% confidence interval [CI], 4.3-17.3 months) had similar OS, compared to 223 patients with undetected mutations (median 10.8 months; 95% CI, 9.0-12.8; p = 0.770).
Although dabrafenib plus trametinib comprises the treatment of choice for patients with lung ADC carrying BRAF V600E mutation, none of our patients received such therapy because of financial issues. Therefore, we evaluated the clinical outcome of patients in the absence of dabrafenib and trametinib treatment. The median progression-free survival (PFS) for pemetrexed/platinum followed by maintenance pemetrexed as first-line therapy was 12.6 (95% CI, 4.3-20.9) months. Notably, three patients remained under the maintenance pemetrexed of first-line pemetrexed/cisplatin therapy for 97, 27, and 17 months without disease progression at the data cut-off date. In addition, two patients received third-line single agent dabrafenib treatment in a clinical trial with short PFS (2.8 and 3.9 months). Among 28 patients had metastatic disease, we observed that patients receiving pemetrexed plus platinum then maintenance pemetrexed as first-line therapy exhibited an OS of 15.5 months (95% CI, 0-38 months), which tended to associate with a longer OS than those receiving other regimen (median 10.8 months; 95% CI, 0-33 months) or those receiving best supportive care (median 9.3 months; p = 0.011) (Figure 3c ).
In the present study, we validated the clinical application of IHC using the VE1 antibody to detect BRAF V600E-mutated lung ADCs from primary lung cancer, metastatic tumors, or malignant pleural effusion cell blocks. We also observed that for patients who were unable to receive BRAF-targeted therapy because of financial issues, pemetrexed-containing regimens might be considered as an important treatment of choice for those with metastatic BRAF V600E-lung ADCs.
The VE1 mouse monoclonal antibody used in the present study constitutes an in vitro diagnostic IHC antibody produced against synthetic peptide sequence (GLATEKSRWSG) that represents the positions from amino acids 596 to 606 in BRAF V600E [21] . This mutation-specific antibody is intended for qualitative staining in sections of formalin-fixed, paraffin-embedded tissue and exhibits a cytoplasmic staining pattern consistent with the cytoplasmic localization of the mutated protein in tumors. This antibody was able to differentiate V600E mutation in the BRAF protein from the wild-type along with other BRAF-mutated proteins [21] . For clinical application, numerous studies have demonstrated that IHC with the VE1 antibody achieved high concordance rates with molecular methods in different types of cancer. The sensitivity and specificity ranged from 85 to 100% and 93 to 100% in melanoma; 89 to 100% and 61.5 to 100% in papillary thyroid carcinomas, and 71 to 100% and 68 to 100% in colorectal carcinomas [11] . Other malignancies, such as primary central nervous system neoplasms [22, 23] , hairy cell leukemia [24] , ameloblastoma [25] , and ovarian carcinoma [26] all showed robust concordance with molecular methods of detection as well [11] . Clinically, the staining in BRAF V600E-mutant positive cases can be weak, moderate, to strong, and the distribution can be uniform, nearly uniform, or heterogeneous in colorectal carcinoma [15] .
In lung cancer, to the best of our knowledge, only two studies provided in-depth evaluation of the clinical feasibility and diagnostic value of IHC with the VE1 antibody for the detection of the BRAF V600E mutation (Table 4) . Sasaki et al. [16] applied a Dako EnVisionTMFLEX detection system with the VE1 antibody and compared these findings with the results of direct sequencing in Japanese lung ADC, demonstrating that the autostainer IHC VE1 assay exhibited excellent sensitivity (100%) in 5 of 5 BRAF V600E-mutated tumors and specificity (95.2%) in 20 of 21 BRAF non-V600E tumors. In a BRAF non-600E mutation cases, a 3-bp insertion in BRAF resulting in the duplication of threonine 599 (599insT) showed positive in the IHC VE1 assay. Another study by Ilie et al. [17] using the VE1 antibody and an automated single-staining system from Ventana Medical Systems demonstrated sensitivity reaching 90% (19 of 21) in BRAF V600E-mutated tumors and perfect specificity (19 of 19, 100%) in all BRAF non-V600E-mutated tumors.
The interpretation criteria of BRAF V600E (VE1) IHC in lung cancer have not been established and different criteria were used by different study groups. The Japanese study group (Sasaki, et al.) used a cut-off value of at least 50% of tumor cells with positive staining irrespective of staining intensity [16] . Ilie et al. used a different method and only cases with a distinct, strong and homogenous signal observed in the cytoplasm of all carcinoma cells were considered positive [17] . The criteria proposed by the manufacturer (Ventana Medical Systems) is positive signal when cells that exhibit unequivocal cytoplasmic staining and the intensity may range from weak to moderate, while negative signal is characterized by an absence of any detectable signal. Our data showed that VE1 IHC in lung cancer is similar to colorectal cancer as the staining intensity may be weak to strong and most positive cases had a near-uniform staining pattern. Therefore, in this study we followed the VE1 IHC interpretation criteria used by the Japanese study group (Sasaki, et al.) and IHC was considered as positive when there was positive cytoplasmic staining in ≥50% of tumor cells. To date, however, no study specifically had examined whether VE1 IHC would cross-react with other driver mutations in lung ADCs. Among all 70 non-BRAF V600E-mutated cases, only one case with ALK fusion (confirmed by positive ALK[D5F3] IHC) provided a false positive result with positive cytoplasmic and nuclear staining in 80% of tumor cells. This sample was validated as carrying the wild-type BRAF gene by direct DNA sequencing; moreover, clinical data showed partial response to an ALK inhibitor (crizotinib) with a progression-free survival (PSF) of 7 months. Among 29 BRAF V600E-mutated cases, only one case (using a bronchial biopsy specimen) yielded a false negative result, which would be associated with inadequate tumor samples. Therefore, we suggest that under certain conditions, such as small tissue samples with a limited number of tumor cells, the BRAF V600E (VE1) IHC test should be more carefully evaluated and rebiopsy for molecular testing should be considered. Nevertheless, together with previous reports, we found that the BRAF V600E (VE1) IHC test was a highly sensitive (94.5%) and specific (98.2) method to detect BRAF V600E mutations in lung ADCs (Table 4) .
As previously reported from European studies, BRAF V600E mutations were more prevalent in females, more likely to arise in light/never-smokers, and associated with a median age of 67 to 69 years [18, 27, 28] . The present study also demonstrated a similar age distribution in pure Asian patients. However, our data showed slight mutation prevalence in East Asian men. On histologic pattern analysis, a previous study of lung ADCs demonstrated that the micropapillary pattern-positive patients with stage IA ADC exhibited worse 5-and 10-year OS rates compared to those of micropapillary pattern-negative patients, indicating micropapillary pattern as being an aggressive tumor feature [29] . In the present study, we observed that the majority of BRAF V600E-mutated lung ADCs presented a micropapillary-predominant pattern, either in primary lung tumors or metastatic sites, which was consistent with other reports [17, 27, 30] . Therefore, patients with BRAF V600E mutated lung ADCs might have shorter survival than those with non-V600E mutations that were non-micropaillary patterns in majority of tumors, which shown in previous studies [17, 31] .
Recently, a phase II trial demonstrated that the combination of dabrafenib and trametinib as the first-line treatment showed clinically meaningful antitumor activity and a manageable safety profile in patients with previously untreated BRAF V600E-mutated metastatic NSCLC [10, 32] . Therefore, the concurrent dabrafenib and trametinib administration is currently considered as an optimal treatment in BRAF V600E-mutant metastatic NSCLC. However, despite clinical benefit, targeted therapies may be associated with issues of unaffordability and increase financial burden in real-world cancer management [33] . In the present study, we observed that patients who received pemetrexed/platinum-based chemotherapy followed by pemetrexed continuation maintenance therapy as the first-line treatment for metastatic disease rather than targeted therapy demonstrated a PFS of 12.6 months and a median OS of 15.5 months. The median OS in this study was comparable to that obtained by patients with advanced nonsquamous NSCLC in the phase III PARAMOUNT trial (13.9 months) [34] . Recently, similar median OS data were reported in studies from Tissot et al. (16 months) [35] and Ding et al. (14.7 months) [36] in Stage IV BRAF V600E-mutant metastatic NSCLC. Other studies demonstrated to a better median OS, which might be attributed to the benefit to targeted therapy with BRAF/MEK inhibitors [37, 38] . Nevertheless, in our study, we reported that a subset of patients with BRAF V600E-mutant metastatic NSCLC may obtain clinical benefit from pemetrexed-based chemotherapy. In particular, a 49-year-old man with initial Stage IV lung ADC who received pemetrexed/cisplatin followed by pemetrexed monotherapy for eight years exhibited favorable outcome and is still under pemetrexed treatment. A similar patient with Stage IIIB NSCLC has also been reported recently, who showed no disease progression for over eight years under pemetrexed treatment [39] .
Some potential limitations of the present study include the retrospective design of the study and the relatively small sample size. In addition, although the treatment modalities in our institutions were standardized, they may have varied as they depended on the individual decision of each physician or the personal choice of each patient. Nevertheless, this study provides important insight on diagnostic method and a potential treatment of choice for lung ADC patients harboring BRAF V600E mutation. Further large scale, multi-center, standardized, and prospective studies are needed to clarify these findings.
Materials and Methods
Study Design
We retrospectively reviewed medical record of primary BRAF V600E-mutated lung ADC at the National Taiwan University Hospital (Taipei, Taiwan). In total, 31 lung cancer specimens with BRAF V600E mutation diagnosed by direct DNA sequencing or reverse transcription-polymerase chain reaction (RT-PCR) were identified. The clinical data of 700 non-BRAF V600E lung ADC patients were retrieved from our previous published cohort study to compare with BRAF V600E-mutated patients [40] . The clinicopathologic characteristics of the 731 patients were recorded including age, gender, smoking status, histological subtype, initial stage [41] , Eastern Cooperative Oncology Group performance status [42] , initial metastatic sites, and chemotherapy/targeted therapy. Progression-free survival was defined as the time of treatment initiation and tumor progression or death from any cause, with censoring of patients who were lost to follow-up. Overall survival was defined as the period from the date of initial diagnosis of Stage IV lung cancer to the date of death (or censored at the date of last follow-up/loss of contact).
For BRAF V600E IHC analyses, we retrieved tumor tissues diagnosed as BRAF V600E mutation-positive and without BRAF V600E, and used the VE1 clone for the IHC assay. Histologic patterns were recorded. Two patients with inadequate tissue specimens were excluded. Finally, 29 patients with lung cancer (93.5%) were included in the VE1 IHC analysis. The 70 lung tumors with mutations other than BRAF V600E or undetected mutations were randomly selected from our 700 cohort patients to determine the specificity of the VE1 IHC assay; these included tumors with BRAF non-V600E mutations, major driver mutations (EGFR, KRAS, HER2, MET ∆14 , ALK, ROS1, and RET), and no-detectable mutations. The study was approved by the Institutional Review Board of the National Taiwan University Hospital (NTUH-Research Ethics Committee number: 201807075RINC; October 1, 2018).
Mutation Analyses
Molecular analyses for BRAF and other major driver alterations were performed. The specimen preparation, DNA/RNA extraction, RT-PCR, and sequencing of EGFR, KRAS, HER2, and MET ∆14 mutations, along with ALK, RET, and ROS1 fusions were performed individually as described previously [40, [43] [44] [45] . A portion of ALK fusions was determined by IHC based on standard protocol [46] . A portion of ROS1 fusions was determined by fluorescence in situ hybridization analyses as previous described [45] . To validate detected BRAF V600E mutations, RT-PCR was performed on RNA samples based on the manufacturer's protocol and as previously described [43] . The primers used were: forward 5 -TCCAGGACCTCAGCGAGAAAGGA-3 ) and reverse (5 -TGATGACTTCTGGTGCCATCCACA-3 ). For BRAF V600E genomic DNA sequencing, the template consisted of 100 ng of genomic DNA. PCR reactions were performed using standard PCR conditions primers. The resulting products were directly sequenced in both directions using the same primers as RT-PCR or DNA sequencing mentioned above. National Center for Biotechnology Information BRAF (NM_004333.5) was used as the reference sequence.
Immunohistochemistry
Tissue sections (4 µm thick) were dewaxed and rehydrated. For hematoxylin-eosin staining, sections were reacted with hemalum followed by counterstaining with eosin. For IHC staining, sections were deparaffinized using EZ Prep™ solution (Ventana Medical Systems, Inc., Tucson, AZ, USA) and subjected to a 64 min pretreatment using Cell Condition 1 solution (Ventana Medical Systems). The slides were incubated with VE1 antibody (Ventana Medical Systems) for 16 min. The Optiview DAB Detection Kit (Ventana Medical Systems) was used to detect protein expression. All sections were counterstained with hematoxylin. The IHC was performed on the Benchmark XT platform (Ventana Medical Systems). The staining intensity was recorded as 0 (negative), 1+ (weak cytoplasmic staining), 2+ (moderate cytoplasmic staining), and 3+ (strong cytoplasmic staining). The percentage of tumor cells with positive staining was recorded semiquantitatively in each case. Nuclear staining was not considered as positive for BRAF V600E according to manufacturer instruction. BRAF V600E (VE1) IHC was considered as positive when there was positive cytoplasmic staining in ≥50% of tumor cells.
Statistical Analyses
For the clinicopathological characteristics of the patients, all categorical variables were analyzed using a chi-square test. PFS and OS curves were plotted using the Kaplan-Meier method. All statistical analyses were performed using Statistical Package for the Social Sciences software for Windows, version 17.0 (SPSS Inc., Chicago, IL, USA).
Conclusions
We observed that using the VE1 antibody for IHC analysis afforded highly sensitivity and specificity to detect BRAF V600E-mutated lung ADCs in tissues from primary lung cancer, metastatic tumors, or malignant pleural effusion cell blocks. Conventional chemotherapy, particularly pemetrexed/platinum-based first-line therapy, may be considered as an important treatment of choice for patients unable to receive the combination of dabrafenib and trametinib yet harboring metastatic BRAF V600E-mutated lung ADC. 
